• ICS (licensed only as part of combination therapy (with LABA and/or LAMA)) are prescribed for people with COPD who have a severe exacerbation, features of asthma or more than 2 exacerbations in one year.
  • Review patients three months following initiation of inhaled ICS as part of combination therapy and stop ICS if there is insufficient response or adverse effects
  • Mucolytic therapy is considered for symptoms of chronic cough with productive sputum and should be reviewed four weeks after commencing therapy, stopping if symptoms have not improved with use
  • Regular review of mucolytic therapy during the annual COPD review should be undertaken and may be stopped if there is no productive cough
  • Review individuals with COPD on separate LAMA and LABA / ICS inhalers and, if appropriate, change to triple therapy inhalers
  • Review antibiotic course length (five-day course recommended) if needed for infective exacerbations of COPD, with sputum cultures for treatment failure
  • Repeated use of 'rescue medication' (steroid and/or antibiotic) (two or more courses per year) should trigger a review to optimise long-term management